Cagrilintide Synonyms / Designations: Cagrilintide, AM833, Long-acting amylin analogue, Dual amylin receptor agonist CAS Number: 1415456-99-3 Molecular Formula: C194H312N54O59S2 Molecular Weight: 4409.01 g/mol Peptide Classification: Synthetic long-acting amylin analogue Purity: 99 % (HPLC, typical) Appearance: White to off-white lyophilised powder Pack Size: Research pack size (varies) Storage: Desiccated, protected from light, stored at 20 C Solubility: Soluble in sterile water and buffered aqueous solutions Description & Mechanism Cagrilintide is a synthetic long-acting analogue of the endogenous peptide hormone amylin, developed for experimental investigation of amylin receptor signalling and metabolic regulation
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
peptides remain viable for extended periods, reducing the need for frequent reconstitution and saving resources in research labs
Melnyk et al, 2000
16 (Suppl 1), 710 (1989)
Moreover, she explains how vigorous exercise may enhance cognition and work against cancer